AP -- Onyx Pharmaceuticals Inc. and partner Bayer ended a late-stage study of its drug Nexavar in skin cancer patient because the drug was not working to improve patients' overall survival rate.
AP -- Onyx Pharmaceuticals Inc. and partner Bayer ended a late-stage study of its drug Nexavar in skin cancer patient because the drug was not working to improve patients' overall survival rate.
